Literature DB >> 24957296

Body mass index delineates ALS from FTD: implications for metabolic health.

R M Ahmed1, E Mioshi, J Caga, M Shibata, M Zoing, L Bartley, O Piguet, J R Hodges, M C Kiernan.   

Abstract

Weight loss and catabolic changes are increasingly recognized as factors that influence outcomes in patients with amyotrophic lateral sclerosis (ALS). An association between disease progression and low BMI has been reported in ALS; however, it remains unknown whether low BMI occurs across all forms of ALS and whether BMI changes with the development of cognitive impairment across the spectrum between ALS and frontotemporal dementia (FTD). One hundred and three ALS patients (56 limb predominant, 18 bulbar predominant, 13 ALS plus, 16 ALSFTD) were recruited and compared to 19 behavioral variant FTD (bvFTD) patients and a group of age-matched healthy controls. BMI was measured at the initial clinical visit. Patients were characterized as underweight, normal, overweight or obese, based on the current World Health Organization (WHO) guidelines. Limb and bulbar ALS patients had significantly lower BMI than ALS plus, ALSFTD, and bvFTD patient groups. When BMI was categorized using WHO guidelines the majority of the limb and bulbar ALS patients were either underweight or normal weight, whilst the majority of the ALS plus, ALSFTD and bvFTD patients were either overweight or obese. On follow-up BMI assessment the limb and bulbar groups tended to decline whilst ALS plus, ALSFTD and bvFTD groups remained stable or increased. BMI is significantly higher in ALS individuals with cognitive deficits. The present findings have prognostic implications for disease progression and may help delineate the metabolic profile across the ALSFTD spectrum.

Entities:  

Mesh:

Year:  2014        PMID: 24957296     DOI: 10.1007/s00415-014-7416-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Nutritional status is a prognostic factor for survival in ALS patients.

Authors:  J C Desport; P M Preux; T C Truong; J M Vallat; D Sautereau; P Couratier
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

2.  EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force.

Authors:  Peter M Andersen; Sharon Abrahams; Gian D Borasio; Mamede de Carvalho; Adriano Chio; Philip Van Damme; Orla Hardiman; Katja Kollewe; Karen E Morrison; Susanne Petri; Pierre-Francois Pradat; Vincenzo Silani; Barbara Tomik; Maria Wasner; Markus Weber
Journal:  Eur J Neurol       Date:  2011-09-14       Impact factor: 6.089

3.  Impaired glucose tolerance in patients with amyotrophic lateral sclerosis.

Authors:  Pierre-Francois Pradat; Gaelle Bruneteau; Paul H Gordon; Luc Dupuis; Dominique Bonnefont-Rousselot; Dominique Simon; Francois Salachas; Philippe Corcia; Vincent Frochot; Jean-Marc Lacorte; Claude Jardel; Christiane Coussieu; Nadine Le Forestier; Lucette Lacomblez; Jean-Philippe Loeffler; Vincent Meininger
Journal:  Amyotroph Lateral Scler       Date:  2010

4.  Hypermetabolism in ALS: correlations with clinical and paraclinical parameters.

Authors:  Jean-Claude Desport; Frédéric Torny; Mathieu Lacoste; Pierre-Marie Preux; Philippe Couratier
Journal:  Neurodegener Dis       Date:  2005       Impact factor: 2.977

Review 5.  Brain lesions and eating disorders.

Authors:  R Uher; J Treasure
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-06       Impact factor: 10.154

Review 6.  Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis.

Authors:  Peter Kühnlein; Hans-Jürgen Gdynia; Anne-Dorte Sperfeld; Beate Lindner-Pfleghar; Albert Christian Ludolph; Mario Prosiegel; Axel Riecker
Journal:  Nat Clin Pract Neurol       Date:  2008-06-17

7.  Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.

Authors:  L Dupuis; P Corcia; A Fergani; J-L Gonzalez De Aguilar; D Bonnefont-Rousselot; R Bittar; D Seilhean; J-J Hauw; L Lacomblez; J-P Loeffler; V Meininger
Journal:  Neurology       Date:  2008-01-16       Impact factor: 9.910

Review 8.  The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis.

Authors:  Michael J Strong
Journal:  Amyotroph Lateral Scler       Date:  2008-12

9.  Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis.

Authors:  Michael J Strong; Gloria M Grace; Morris Freedman; Cathy Lomen-Hoerth; Susan Woolley; Laura H Goldstein; Jennifer Murphy; Christen Shoesmith; Jeffery Rosenfeld; P Nigel Leigh; Lucie Bruijn; Paul Ince; Denise Figlewicz
Journal:  Amyotroph Lateral Scler       Date:  2009-06

10.  Hypermetabolism in ALS patients: an early and persistent phenomenon.

Authors:  C Bouteloup; J-C Desport; P Clavelou; N Guy; H Derumeaux-Burel; A Ferrier; P Couratier
Journal:  J Neurol       Date:  2009-03-22       Impact factor: 4.849

View more
  8 in total

1.  Body Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans.

Authors:  Daniela Mariosa; John D Beard; David M Umbach; Rino Bellocco; Jean Keller; Tracy L Peters; Kelli D Allen; Weimin Ye; Dale P Sandler; Silke Schmidt; Fang Fang; Freya Kamel
Journal:  Am J Epidemiol       Date:  2017-03-01       Impact factor: 4.897

Review 2.  Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders.

Authors:  Juan Miguel Godoy-Corchuelo; Luis C Fernández-Beltrán; Zeinab Ali; María J Gil-Moreno; Juan I López-Carbonero; Antonio Guerrero-Sola; Angélica Larrad-Sainz; Jorge Matias-Guiu; Jordi A Matias-Guiu; Thomas J Cunningham; Silvia Corrochano
Journal:  Biomedicines       Date:  2022-05-10

3.  Extensive phenotypic characterisation of a human TDP-43Q331K transgenic mouse model of amyotrophic lateral sclerosis (ALS).

Authors:  Jodie A Watkins; James J P Alix; Pamela J Shaw; Richard J Mead
Journal:  Sci Rep       Date:  2021-08-17       Impact factor: 4.379

4.  Cognition and eating behavior in amyotrophic lateral sclerosis: effect on survival.

Authors:  R M Ahmed; J Caga; E Devenney; S Hsieh; L Bartley; E Highton-Williamson; E Ramsey; M Zoing; G M Halliday; O Piguet; J R Hodges; M C Kiernan
Journal:  J Neurol       Date:  2016-06-03       Impact factor: 4.849

Review 5.  Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism.

Authors:  Pauline Vercruysse; Didier Vieau; David Blum; Åsa Petersén; Luc Dupuis
Journal:  Front Mol Neurosci       Date:  2018-01-19       Impact factor: 5.639

6.  Genetic induction of hypometabolism by ablation of MC4R does not suppress ALS-like phenotypes in the G93A mutant SOD1 mouse model.

Authors:  Shachee Doshi; Preetika Gupta; Robert G Kalb
Journal:  Sci Rep       Date:  2017-10-13       Impact factor: 4.379

7.  Body Complexion and Circulating Lipids in the Risk of TDP-43 Related Disorders.

Authors:  Noelia Esteban-García; Luis C Fernández-Beltrán; Juan Miguel Godoy-Corchuelo; Jose L Ayala; Jordi A Matias-Guiu; Silvia Corrochano
Journal:  Front Aging Neurosci       Date:  2022-03-25       Impact factor: 5.750

Review 8.  Recent advances in amyotrophic lateral sclerosis.

Authors:  Nilo Riva; Federica Agosta; Christian Lunetta; Massimo Filippi; Angelo Quattrini
Journal:  J Neurol       Date:  2016-03-30       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.